• Most study participants understand research goals (Reuters)

    Fri, 04 Jul 2008 07:29:02 PDT
    Reuters - People who take part in clinical trials often do so out of a desire to advance scientific knowledge and to help others, a new international study demonstrates.

  • Tongue-Driven Device Aids Handicapped (HealthDay)

    Thu, 03 Jul 2008 20:47:58 PDT
    HealthDay - THURSDAY, July 3 (HealthDay News) -- A tongue drive system that enables severely disabled people to operate powered wheelchairs and to perform other tasks has been developed by engineers at the Georgia Institute of Technology.

  • Freeze-Dried Formula May Block HIV Virus in Breast Milk (HealthDay)

    Thu, 03 Jul 2008 20:47:52 PDT
    HealthDay - THURSDAY, July 2 (HealthDay News) -- In developing countries where breast-feeding is a necessity, and HIV is rampant, the risk of disease transmission through breast milk might be reduced if infants were first fed a freeze-dried formula full of good bacteria that could capture and potentially destroy the deadly virus.

  • S.African addicts turn to AIDS medication to get high (AFP)

    Wed, 02 Jul 2008 10:07:25 PDT
    AFP - South African AIDS patients in Durban are under siege from drug addicts who rob them of their antiretroviral treatment to get high, the provincial health department said Wednesday.

  • Bush urges Congress to pass AIDS funds (Reuters)

    Wed, 02 Jul 2008 09:29:12 PDT
    Reuters - President George W. Bush urged Congress on Wednesday to approve funds to fight AIDS in Africa and other countries, and said the issue was high on his agenda for a Group of Eight summit in Japan next week.

  • Death Rates for HIV Patients Decrease Dramatically (HealthDay)

    Tue, 01 Jul 2008 20:46:56 PDT
    HealthDay - TUESDAY, July 1 (HealthDay News) -- Death rates for HIV-infected people lucky enough to get their hands on antiretroviral medications have decreased dramatically since the introduction of these drugs in 1996, new British research shows.

  • Anti-retroviral drug cocktails slash AIDS deaths: study (AFP)

    Tue, 01 Jul 2008 15:39:54 PDT
    AFP - Anti-retroviral drug therapy has slashed AIDS death rates in the first five years after infection to equal the normal death rates in developed countries, scientists said Tuesday.

  • People with HIV living longer, study shows (Reuters)

    Tue, 01 Jul 2008 13:25:44 PDT
    Reuters - People with HIV in the developed world are no more likely to die in the first five years following infection than men and women in the general population, British researchers said on Tuesday.

  • Political will helping India's AIDS battle: U.N. (Reuters)

    Mon, 30 Jun 2008 08:13:31 PDT
    Reuters - A strong political will was stimulating India's fight against AIDS, raising hopes of controlling its spread in the country with the world's third-largest caseload, the U.N.'s AIDS agency said on Monday.

  • NYC urges docs to do routine HIV testing on adults (AP)

    Thu, 26 Jun 2008 23:19:44 PDT
    AP - Health officials are trying to persuade doctors to offer HIV tests to nearly every patient in a New York City community hit harder than most by AIDS.

DESCRIPTION

ATRIPLA™ is a fixed dose combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate (tenofovir DF). SUSTIVA® is the brand name for efavirenz, a non-nucleoside reverse transcriptase inhibitor. EMTRIVA® is the brand name for emtricitabine, a synthetic nucleoside analog of cytidine. VIREAD® is the brand name for tenofovir DF, which is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. VIREAD and EMTRIVA are the components of TRUVADA®.

ATRIPLA Tablets are for oral administration. Each tablet contains 600 mg of efavirenz, 200 mg of emtricitabine, and 300 mg of tenofovir DF (which is equivalent to 245 mg of tenofovir disoproxil) as active ingredients. The tablets include the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablets are film-coated with a coating material containing black iron oxide, polyethylene glycol, polyvinyl alcohol, red iron oxide, talc, and titanium dioxide.

Efavirenz: Efavirenz is chemically described as (S) - 6 - chloro - 4 - (cyclopropylethynyl) - 1,4 - dihydro - 4 - (trifluoromethyl) - 2H - 3,1 - benzoxazin - 2 - one. Its molecular formula is C14H9ClF3NO2 and its structural formula is:
Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It is practically insoluble in water (<10 μg/mL).

Emtricitabine: The chemical name of emtricitabine is 5 - fluoro - 1 - (2R,5S) - [2 - (hydroxymethyl) - 1,3 - oxathiolan - 5 - yl]cytosine. Emtricitabine is the (-) enantiomer of a thio analog of cytidine, which differs from other cytidine analogs in that it has a fluorine in the 5-position.
It has a molecular formula of C8H10FN3O3S and a molecular weight of 247.24. It has the following structural formula:
Emtricitabine is a white to off-white crystalline powder with a solubility of approximately 112 mg/mL in water at 25 °C.
Tenofovir disoproxil fumarate: Tenofovir DF is a fumaric acid salt of the bisisopropoxycarbonyloxymethyl ester derivative of tenofovir. The chemical name of tenofovir disoproxil fumarate is 9 - [(R) - 2[[bis[[ (isopropoxycarbonyl)oxy] - methoxy] phosphinyl] methoxy] propyl] adenine fumarate (1:1). It has a molecular formula of C19H30N5O10P • C4H4O4 and a molecular weight of 635.52. It has the following structural formula:

Tenofovir DF is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in water at 25 °C.